Journey Medical Corporation

Journey Medical Corporation

DERMยทNASDAQ

$6.02

+2.0%
HealthcareDrug Manufacturers - Specialty & Generic

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

At a Glance

Live Snapshot
Market Cap$165.68M
EPS-0.4700
P/E Ratio-16.52
Earnings Date08/11/2026
0.00%
Dividend Yield
3Y-
5Y-
10Y-
0.00%
Dividend Payout Ratio
3Y-
5Y-
10Y-
Journey Medical Corporation

Journey Medical Corporation Dividend History

DERM ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

DERM Dividend Payment History

DERM ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
derm

Journey Medical Corporation Payout Ratio Analysis

DERM ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-11.43M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.